Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Bought by M&T Bank Corp

M&T Bank Corp boosted its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 16.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,194 shares of the company’s stock after acquiring an additional 1,851 shares during the quarter. M&T Bank Corp’s holdings in Roivant Sciences were worth $156,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ROIV. Gladius Capital Management LP acquired a new stake in Roivant Sciences during the third quarter worth $35,000. US Bancorp DE grew its stake in shares of Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after buying an additional 1,948 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after buying an additional 1,288 shares in the last quarter. Quarry LP grew its stake in shares of Roivant Sciences by 50.0% in the third quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after buying an additional 2,500 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Roivant Sciences by 550.1% in the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after buying an additional 6,667 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

ROIV has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences presently has a consensus rating of “Buy” and an average price target of $18.08.

Roivant Sciences Stock Performance

ROIV opened at $10.66 on Friday. Roivant Sciences Ltd. has a one year low of $9.76 and a one year high of $13.06. The company has a market cap of $7.61 billion, a P/E ratio of -71.06 and a beta of 1.26. The business’s 50-day simple moving average is $10.81 and its 200-day simple moving average is $11.50.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the transaction, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $10.65, for a total value of $1,065,000.00. Following the completion of the sale, the chief operating officer now directly owns 896,869 shares of the company’s stock, valued at approximately $9,551,654.85. This trade represents a 10.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,388,170 shares of company stock worth $27,612,299. 7.90% of the stock is currently owned by insiders.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.